Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.37 |
| ▸ | STS | P08842 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3755420 | 0.89 | HRH3 (0.37) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL6462748 | 0.88 | LMNA (0.52) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL6569575 | 0.88 | LMNA (0.52) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL13049214 | 0.86 | ESR1 (0.45) | HSD17B1LMNAMAPTHSD17B10ESR1 | |
| SCHEMBL13049217 | 0.86 | HRH3 (0.36) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL13079253 | 0.85 | LMNA (0.49) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL6467449 | 0.83 | HSD17B1 (0.64) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL3102817 | 0.83 | HSD17B1 (0.64) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL5973996 | 0.80 | LMNA (0.44) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 | |
| SCHEMBL3744410 | 0.80 | LMNA (0.44) | HSD17B1LMNAMAPTRECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7838516-B2 | 15 β-substituted steroids having selective estrogenic activity | N.V. ORGANON (NL) | 2010-11-23 | — | — | US | disclosed |
| US-7838516-B2 | 15 β-substituted steroids having selective estrogenic activity | N.V. ORGANON (NL) | 2010-11-23 | — | — | US | disclosed |
| EP-1805201-B1 | 15beta-SUBSTITUTED STEROIDS HAVING SELECTIVE ESTROGENIC ACTIVITY | ORGANON NV (NL) | 2008-11-19 | — | — | EP | disclosed |
| US-20070254860-A1 | 15 Beta-Substituted Steroids Having Selective Estrogenic Activity | N.V. ORGANON (NL) | 2007-11-01 | — | — | US | disclosed |
| US-20070254860-A1 | 15 Beta-Substituted Steroids Having Selective Estrogenic Activity | N.V. ORGANON (NL) | 2007-11-01 | — | — | US | disclosed |
| EP-1805201-A1 | 15B-SUBSTITUTED STEROIDS HAVING SELECTIVE ESTROGENIC ACTIVITY | N.V. Organon (NL) | 2007-07-11 | — | — | EP | disclosed |
| WO-2006027347-A1 | 15β-SUBSTITUTED STEROIDS HAVING SELECTIVE ESTROGENIC ACTIVITY | N.V. ORGANON (NL) | 2006-03-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254860-A1 | 15 Beta-Substituted Steroids Having Selective Estrogenic Activity | HSD17B11, ESR2, CYP19A1 | HSD17B1 15/4885LMNA 2504/4885MAPT 4868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.